---
title: "Kexing Biopharm Co., Ltd. (688136.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688136.SH.md"
symbol: "688136.SH"
name: "Kexing Biopharm Co., Ltd."
industry: "Biotechnology"
datetime: "2026-05-20T01:58:09.519Z"
locales:
  - [en](https://longbridge.com/en/quote/688136.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688136.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688136.SH.md)
---

# Kexing Biopharm Co., Ltd. (688136.SH)

## Company Overview

Kexing Biopharm Co., Ltd., a biopharmaceutical company, engages in the research and development, production, and sale of recombinant protein drugs and microecological preparations in China, the European Union, Brazil, the Philippines, and Indonesia. The company focuses on oncology, immunology, and degenerative diseases; and develops new antibodies, proteins, nucleic acid drugs, and antiviral therapy, as well as for the treatment of tumor, autoimmune, metabolic diseases, and other therapeutic fields. It also develops GB05 human interferon a1b inhalation solution that is in Phase III clinical trial; GB-K02, an human granulocyte colony-stimulating factor injection in Phase III clinical trial; GB08, an growth hormone that has completed Phase I clinical trial; GB10 for fundus diseases; GB12 for atopic dermatitis; GB18 for cancer cachexia; GB23 for solid tumors; GB24 for inflammatory bowel diseases; and GB25, an tri-specific antibody for colorectal cancer. In addition, the company’s products include drugs, such as human erythropoietin, human interferon a1b and human granulocyte colony-stimulating factor injections, albumin-bound paclitaxel, infliximab injection, combined clostridium butyricum, and bifidobacterium powder/capsule.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | CN Market |
| Website | [www.kexing.com](https://www.kexing.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: C (0.47)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 49 / 81 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 4.37% |  |
| Net Profit YoY | 150.93% |  |
| P/B Ratio | 2.91 |  |
| Dividend Ratio | 0.31% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 5016573415.56 |  |
| Revenue | 1459598899.24 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 6.61% | C |
| Profit Margin | 7.67% | B |
| Gross Margin | 58.65% | B |
| Revenue YoY | 4.37% | C |
| Net Profit YoY | 150.93% | A |
| Total Assets YoY | 9.29% | B |
| Net Assets YoY | 3.64% | C |
| Cash Flow Margin | 60.24% | C |
| OCF YoY | 4.37% | C |
| Turnover | 0.44 | C |
| Gearing Ratio | 50.47% | C |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Kexing Biopharm Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "4.37%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "150.93%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.91",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.31%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "5016573415.56",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "1459598899.24",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "6.61%",
          "rating": "C"
        },
        {
          "name": "Profit Margin",
          "value": "7.67%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "58.65%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "4.37%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "150.93%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "9.29%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "3.64%",
          "rating": "C"
        },
        {
          "name": "Cash Flow Margin",
          "value": "60.24%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "4.37%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.44",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "50.47%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 46.32 | 19/81 | 191.48 | 57.70 | 49.06 |
| PB | 3.00 | 45/81 | 5.30 | 4.23 | 3.59 |
| PS (TTM) | 3.55 | 6/81 | 6.42 | 4.78 | 4.06 |
| Dividend Yield | 0.30% | 34/81 | 0.26% | 0.23% | 0.18% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Sunshine Guojian Pharmaceutical (688336.SH) | A | A | B | A | B | A |
| 02 | AMOYTOP (688278.SH) | A | A | A | A | B | A |
| 03 | BeOne Medicines (688235.SH) | B | A | B | C | A | B |
| 04 | RemeGen (688331.SH) | A | A | C | C | B | B |
| 05 | InnoCare Pharma (688428.SH) | B | A | D | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-07T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 24.95 |
| Highest Target | 31.00 |
| Lowest Target | 31.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/688136.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/688136.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/688136.SH/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**